11/14/2024
4:50 PM | Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SC 13G/A | |
11/14/2024
3:33 PM | PERCEPTIVE ADVISORS LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
11/14/2024
8:44 AM | Deep Track Capital, LP (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
11/14/2024
8:35 AM | Avoro Capital Advisors LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
11/12/2024
9:34 AM | FMR LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
11/08/2024
3:53 PM | Albers Jeffrey W. (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/28/2024
3:41 PM | Albers Jeffrey W. (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
|
10/25/2024
3:28 PM | Albers Jeffrey W. (Reporting)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/23/2024
1:10 PM | Deutsch Peter E. (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G | |
10/22/2024
2:24 PM | BlackRock, Inc. (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G | |
10/15/2024
5:10 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/02/2024
11:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
10/01/2024
5:26 PM | Sloan Sheldon (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
10/01/2024
5:34 PM | Sloan Sheldon (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2024
3:04 PM | Burrows Scott L (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/07/2024
8:12 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 424B3 | |
08/07/2024
3:17 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/10/2024
8:48 AM | FMR LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
05/30/2024
3:33 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/15/2024
6:40 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/09/2024
3:08 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
04/29/2024
11:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
04/25/2024
3:40 PM | Fairmount Funds Management LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13D/A | |
04/25/2024
3:55 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/23/2024
5:22 PM | Avoro Capital Advisors LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
04/18/2024
7:24 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form S-1
Registration statement under Securities Act of 1933 | |
04/01/2024
11:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
04/01/2024
11:15 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
03/20/2024
6:14 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form PRE 14A | |
03/18/2024
7:31 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/11/2024
7:19 AM | FMR LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
03/01/2024
5:14 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 10-K/A | |
02/29/2024
4:06 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/29/2024
3:07 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/20/2024
8:21 PM | Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
Turtle Cameron (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2024
7:47 PM | Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SC 13G/A | |
02/14/2024
3:37 PM | EcoR1 Capital, LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
02/14/2024
8:08 AM | Avoro Capital Advisors LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G | |
02/14/2024
7:56 AM | Deep Track Capital, LP (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
02/14/2024
6:02 AM | RTW INVESTMENTS, LP (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G | |
02/13/2024
5:46 PM | BCLS II Equity Opportunities, LP (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
Strange: Why is Amazon suddenly yielding 39.70%? (Ad) Something big is happening with Amazon stock…
While most investors collect ZERO dividends from Amazon…
A small group just discovered a "backdoor" way to collect yields up to 39.70%! Click here to see this breakthrough before everyone else → |
02/13/2024
8:39 AM | Polar Capital Holdings Plc (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
02/09/2024
9:20 AM | FMR LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G | |
02/08/2024
3:36 PM | INTEGRATED CORE STRATEGIES LLC (0001319244) (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G/A | |
02/06/2024
8:37 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 424B3 | |
02/05/2024
4:25 PM | McKenna Mark C. (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
02/05/2024
4:29 PM | McKenna Mark C. (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/05/2024
6:36 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/02/2024
7:23 PM | King-Jones Heidy (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
7:27 PM | Burrows Scott L (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
7:31 PM | Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
Turtle Cameron (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/18/2024
3:26 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/29/2023
4:00 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Co-Invest L.P. (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Fairmount Healthcare Fund L.P. (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/29/2023
4:00 PM | Fairmount Funds Management LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13D/A | |
12/26/2023
8:56 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form D
Notice of Exempt Offering of Securities | |
12/22/2023
5:00 PM | Burrows Scott L (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/22/2023
4:00 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
12/22/2023
3:32 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form S-1
Registration statement under Securities Act of 1933 | |
12/13/2023
2:50 PM | PERCEPTIVE ADVISORS LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13G | |
12/11/2023
4:41 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Co-Invest L.P. (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Fairmount Healthcare Fund L.P. (Reporting)
Harwin Peter Evan (Reporting)
Kiselak Tomas (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/08/2023
7:45 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/30/2023
4:18 PM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 424B3 | |
11/29/2023
4:08 PM | Fairmount Funds Management LLC (Filed by)
Spyre Therapeutics, Inc. (Subject)
Spyre Therapeutics (Subject)
| Form SC 13D/A | |
11/28/2023
6:33 AM | Spyre Therapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/27/2023
3:27 PM | Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
Stelzer Laurie (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
11/27/2023
3:32 PM | Albers Jeffrey W. (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
11/27/2023
3:33 PM | Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
Stelzer Laurie (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/27/2023
3:36 PM | Albers Jeffrey W. (Reporting)
Spyre Therapeutics, Inc. (Issuer)
Spyre Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/22/2023
7:45 PM | Aeglea BioTherapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/20/2023
11:15 PM | Aeglea BioTherapeutics, Inc. (Filer)
Spyre Therapeutics (Filer)
| Form EFFECT | |
